Thrombosomes

BIOLOGICAL3 trials

Sponsors

Cellphire Therapeutics, Inc.

Conditions

Bone Marrow AplasiaHealthyHematologic DiseasesHematologic MalignancyMyelodysplastic SyndromesMyeloproliferative DisordersPlatelet RefractorinessThrombocytopenia

Early Phase 1

Evaluation of the Safety and Immunogenicity of Autologous Thrombosomes® in Healthy Human Subjects; A Microdose Escalation Study (Cohorts 1 - 4) and Repeat Microdose Immunogenicity Study (Cohort 5)

CompletedNCT02223117

Cellphire Therapeutics, Inc.Healthy

Start: 2014-09-30End: 2016-07-21Updated: 2017-12-13

Phase 1

Thrombosomes® in Bleeding Thrombocytopenic Patients

CompletedNCT03394755

Cellphire Therapeutics, Inc.Bone Marrow Aplasia, Hematologic Diseases, Thrombocytopenia

Start: 2018-03-19End: 2019-09-25Updated: 2023-04-14

Phase 2

Thrombosomes® in Bleeding Thrombocytopenic Patients Study

TerminatedNCT04631211

Cellphire Therapeutics, Inc.Bone Marrow Aplasia, Hematologic Malignancy, Myelodysplastic Syndromes +3

Start: 2021-03-05End: 2022-01-07Updated: 2023-05-25